Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02452424
Title A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Plexxikon
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
HonorHealth Research Institute Scottsdale Arizona 85258 United States Details
Marin Cancer Care Greenbrae California 94904 United States Details
Ronald Reagan UCLA Medical Center Los Angeles California 90095 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Washington University St. Louis Siteman Cancer Center Saint Louis Missouri 63130 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Medical University Health Hollings Cancer Center Charleston South Carolina 29425 United States Details
Vanderbilt Ingram Cancer Center Nashville Tennessee 37212 United States Details
South Texas Accelerated Research Therapeutics San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field